{"id":992122,"date":"2026-08-07T07:33:46","date_gmt":"2026-08-07T11:33:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/"},"modified":"2026-08-07T07:33:46","modified_gmt":"2026-08-07T11:33:46","slug":"faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/","title":{"rendered":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference<\/b><\/p>\n<p><i>\u2014 The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8<\/i><\/p>\n<p><i>\u2014 These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201)<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nFaeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K\/AKT\/mTOR pathway, will present translational data and pharmacokinetic\/pharmacodynamic (PK\/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP Cancer), held August 7-8 in New York.<\/p>\n<p>\nThe poster titled &#8220;Exposure\/Response Analysis of an Oral Multi-Node PI3K\/AKT\/mTOR Pathway Inhibitor Combination of Serabelisib and Sapanisertib&#8221; will be presented on August 8 between 10:25 and 11:30 AM at the New York Marriott Marquis in New York, NY (Poster #9).<\/p>\n<p>\nData to be reported include a PK\/PD analysis that integrates skin biopsy data and PK modeling from earlier third-party clinical trials of serabelisib and sapanisertib. Together, these data informed selection of 3 mg sapanisertib and 200 mg serabelisib three days a week as the recommended Phase 2 dose for PIKTOR in the ongoing Phase 2 trial in second-line advanced endometrial cancer, Study FTH-PIK-201 (NCT06463028).<\/p>\n<p>\nA copy of the poster will be made available in the Investors section of Faeth&#8217;s website at the start of the poster session.<\/p>\n<p><b>About PIKTOR<\/b><\/p>\n<p>\nPIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1\/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K\/AKT\/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated by year-end 2026. PIKTOR is also being evaluated in a Phase 1b\/2 trial in HR+\/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.<\/p>\n<p><b>About Faeth Therapeutics<\/b><\/p>\n<p>\nFaeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company\u2019s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.faeththerapeutics.com&amp;esheet=54585580&amp;newsitemid=20260807091302&amp;lan=en-US&amp;anchor=www.faeththerapeutics.com&amp;index=1&amp;md5=d3dc3d512b879f93043027b9d0ac0818\">www.faeththerapeutics.com<\/a> and follow the Company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F71552694%2F&amp;esheet=54585580&amp;newsitemid=20260807091302&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=a2f372047d9c0d25612ae07349be4b2c\">LinkedIn<\/a>.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201con track\u201d and similar expressions, although not all forward-looking statements contain these words. These statements include, but are not limited to, statements regarding: the content, timing and presentation of data at the STOP Cancer conference; the Company\u2019s interpretation of preclinical, pharmacokinetic and pharmacodynamic data and the conclusions the Company draws from that data, including with respect to dose and schedule selection for PIKTOR; the Company\u2019s expectations regarding its pipeline and development plans, including the Phase 2 trial of PIKTOR in advanced endometrial cancer and the anticipated timing of topline data, and the Phase 1b\/2 trial of PIKTOR in HR+\/HER2- advanced breast cancer and the anticipated timing of interim data; and the potential therapeutic benefits, tolerability profile and differentiation of PIKTOR.<\/p>\n<p>\nForward-looking statements are based on management\u2019s current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company\u2019s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to clinical development and the conduct, timing and results of clinical trials; the risk that results from preclinical studies, earlier clinical trials, modeling or other exploratory analyses may not be predictive of results in ongoing or future clinical trials; the Company\u2019s need for additional financing; its limited operating history and history of operating losses; risks related to the integration of Faeth; the Company\u2019s ability to satisfy applicable Nasdaq listing requirements and to maintain the listing of its common stock; and the other risks and uncertainties described under the headings \u201cRisk Factors\u201d and \u201cSummary of Risk Factors\u201d in the Company\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 30, 2026, its Quarterly Report on Form 10-Q filed with the SEC on August 4, 2026, and its definitive proxy statement filed with the SEC on April 27, 2026, as well as in the Company\u2019s subsequent filings. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260807091302\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260807091302\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Matthew Biegler, SVP, Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:matt@faeththerapeutics.com\">matt@faeththerapeutics.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Patrick Schmidt, Consort Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:faeththerapeutics@consortpartners.com\">faeththerapeutics@consortpartners.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260807091302\/en\/2871053\/3\/Faeth_Therapeutics_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference \u2014 The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 \u2014 These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K\/AKT\/mTOR pathway, will present translational data and pharmacokinetic\/pharmacodynamic (PK\/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP Cancer), held &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992122","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference \u2014 The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 \u2014 These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K\/AKT\/mTOR pathway, will present translational data and pharmacokinetic\/pharmacodynamic (PK\/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP Cancer), held &hellip; Continue reading &quot;Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T11:33:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Faeth Therapeutics to Present PK\\\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference\",\"datePublished\":\"2026-08-07T11:33:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/\"},\"wordCount\":961,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/\",\"name\":\"Faeth Therapeutics to Present PK\\\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-07T11:33:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Faeth Therapeutics to Present PK\\\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/","og_locale":"en_US","og_type":"article","og_title":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk","og_description":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference \u2014 The data will be presented at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer conference on August 8 \u2014 These data collectively informed PIKTOR dose selection in the ongoing Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201) AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K\/AKT\/mTOR pathway, will present translational data and pharmacokinetic\/pharmacodynamic (PK\/PD) analysis for PIKTOR, its oral combination of serabelisib and sapanisertib, at the 2026 Summit for Novel Therapeutics in Oncology &amp; Precision Medicine in Cancer (STOP Cancer), held &hellip; Continue reading \"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-07T11:33:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference","datePublished":"2026-08-07T11:33:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/"},"wordCount":961,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/","name":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-07T11:33:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260807091302r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-to-present-pk-pd-modeling-that-informed-piktor-dose-selection-in-ongoing-fth-pik-201-trial-at-upcoming-scientific-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Faeth Therapeutics to Present PK\/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992122"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}